RENNIE FRESH 680 MG / 80 MG CHEWABLE TABLETS
Active substance(s): CALCIUM CARBONATE / MAGNESIUM CARBONATE HEAVY / CALCIUM CARBONATE / MAGNESIUM CARBONATE HEAVY / CALCIUM CARBONATE / MAGNESIUM CARBONATE HEAVY
NAME OF THE MEDICINAL PRODUCT
Rennie Fresh 680 mg / 80 mg chewable tablets
QUALITATIVE AND QUANTITATIVE COMPOSITION
Calcium Carbonate 680.0 mg
Heavy Magnesium Carbonate 80.0 mg
Also contains sucrose
For full list of excipients, see section 1
A square cream white tablet with occasional slight speckles, rounded corners,
bevelled edges and concave faces, engraved ‘Rennie’ on both sides.
For the relief of indigestion, heartburn, nervous indigestion, hyperacidity, flatulence,
upset stomach, dyspepsia, biliousness, overindulgence in food and drink, indigestion
Posology and method of administration
Tablets to be taken orally, sucked or chewed.
Adults and Children over 12 years:
Two tablets to be sucked or chewed as a single dose, preferably to be taken one hour
after meals and before going to bed but also in between in case of heartburn or gastric
pain. A maximum daily dose of 8 g calcium carbonate, corresponding to 10 tablets, a
day must not be exceeded.
Not recommended for children under 12 years.
As with all antacids, if symptoms persist despite 14 days of continuous therapy,
diagnostic measures are strongly recommended in order to rule out a more serious
Rennie should not be administered to patients with:
• Hypersensitivity to any of the ingredients of the product
• Hypercalcaemia and/or conditions resulting in hypercalcaemia
• Nephrolithiasis due to calculi containing calcium deposits
• Severe renal insufficiency
Special warnings and precautions for use
• Prolonged use should be avoided.
• The stated dose should not be exceeded. If, after 14 days of treatment, symptoms
persist or only partly disappear the patient should consult a doctor.
• Caution should be exercised in patients with mild to moderate impairment of renal
function (see section 4.3 – contraindication in severe renal insufficiency). If Rennie is
used in such patients, plasma calcium, phosphate and magnesium levels should be
• Long term uses at high doses can result in undesirable effects such as
hypercalcaemia, hypermagnesaemia and milk-alkali syndrome, especially in patients
with renal insufficiency.
• Rennie should not be used in patients with hypercalciuria (see also section 4.3).
Prolonged use increases the risk of formation of renal calculi.
• This product should not be taken with large amounts of milk or dairy products.
• Patients with rare hereditary problems of fructose intolerance, glucose-galactose
malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Interaction with other medicinal products and other forms of interaction
Changes in gastric acidity, such as that caused by the ingestion of antacids, can affect
the rate and degree to which some concurrently administered medicines are absorbed.
• It has been shown that antacids which contain calcium or magnesium may form
complexes with certain substances e.g., antibiotics (such as tetracyclines and
quinolones), and cardiac glycosides (e.g. digoxin), levothyroxine, and eltrombopag,
resulting in decreased absorption. This should be borne in mind when concomitant
administration is considered.
• Calcium salts reduce the absorption of fluorides and iron-containing products, and
calcium salts and magnesium salts can hinder the absorption of phosphates.
• Thiazide diuretics reduce the urinary excretion of calcium. Due to an increased risk
of hypercalcaemia, serum calcium should be regularly monitored during concomitant
use of thiazide diuretics.
Therefore it is preferable to take the antacid separately from other drugs, allowing at
least 4 hours before or after taking eltrombopag and a 1-2 hour interval for all other
Fertility, pregnancy and lactation
No increased risk of congenital defects has been observed after the use of this product
during pregnancy and it can be used during pregnancy and lactation if taken as
instructed but prolonged intake of high dosages should be avoided. Pregnant women
should limit the use of these products to the maximum recommended daily doses (see
During pregnancy and lactation, it has to be taken into account that the tablets provide
a substantial amount of calcium in addition to dietary calcium intake. For this reason,
pregnant women should strictly limit their use of tablets to the maximum
recommended daily dose and avoid concomitant, excessive intake of milk and dairy
products. This warning is to prevent calcium overload which might result in milkalkali syndrome.
Effects on ability to drive and use machines
No effects on ability to drive and use machines have been observed.
The listed adverse drug reactions are based on spontaneous reports, thus an
organisation according to CIOMS III categories of frequency is not possible.
Immune System Disorders:
Hypersensitivity reactions have very rarely been reported. Clinical symptoms may
include rash, urticaria, angioedema and anaphylaxis.
Metabolism and Nutrition Disorders:
Especially in patients with impaired renal function, prolonged use of high doses can
result in hypermagnesaemia or hypercalcaemia and alkalosis which may give rise to
gastric symptoms and muscular weakness (see below).
Nausea, vomiting, stomach discomfort and diarrhoea may occur.
Musculoskeletal and Connective Tissue Disorders:
Muscular weakness may occur.
Undesirable effects occurring in the context of milk-alkali syndrome (see 4.9):
Ageusia may occur in the context of milk-alkali syndrome.
General Disorders and Administration Site Conditions:
Calcinosis and asthenia may occur in the context of milk-alkali syndrome.
Nervous System Disorders:
Headache may occur in the context of milk-alkali syndrome.
Renal and Urinary Disorders:
Azotemia may occur in the context of milk-alkali syndrome.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard.
Especially in patients with impaired renal function, prolonged use of high doses can
result in renal insufficiency, hypermagnesaemia, hypercalcaemia and alkalosis which
may give rise to gastrointestinal symptoms (nausea, vomiting, constipation) and
muscular weakness. In these cases, the intake of the product should be stopped and
adequate fluid intake encouraged. In severe cases of overdosage (e.g. milk-alkali
syndrome), a health care professional must be consulted because other measures of
rehydration (e.g. infusions) might be necessary.
Pharmacotherapeutic Classification: Antacids
ATC codes: Calcium carbonate: A02AC01
Magnesium carbonate: A02AA01
Calcium and magnesium carbonates react with excess acid in the gastric medium to
produce soluble chlorides.
CaCO3 + 2HCl => CaCl2 + H2O + CO2
MgCO3 + 2HCl => MgCl2 + H2O + CO2
Calcium carbonate has a rapid and powerful neutralising action. This effect is
increased by the addition of magnesium carbonate which also has a strong
In healthy volunteers, a significant increase in the pH of stomach contents above
baseline pH was achieved between 1 and 6 minutes after dosing.
A small amount of calcium and magnesium may be absorbed, but in healthy subjects
is usually rapidly excreted by the kidney. The soluble chlorides produced by the
reaction of calcium and magnesium with gastric acid react, in turn, with intestinal,
biliary and pancreatic secretions to form insoluble salts, which are excreted in the
Preclinical safety data
There is no information of relevance to the safety assessment in addition to
what is stated in other parts of the Summary of Product Characteristics.
List of excipients
Maize starch, pregelatinised
Paraffin, light liquid
Xylitab 100 (xylitol, polydextrose)
Special precautions for storage
Do not store above 25°C.
Nature and contents of container
Tablets are packed in a hard tempered aluminium foil (20µm)/clear thermoformable
PVC (150µm) bubble pack, with six or twelve tablets per strip. 1, 3, 4, 6 or 8 strips
are packed in a cardboard carton.
12 tablet Pocket Pack - Tablets are packed in a hard tempered aluminium foil
(20µm)/clear thermoformable PVC (250µm) bubble pack, with six tablets per strip.
Two strips are packed in a cardboard pocket pack.
Pack sizes: 6, 12, 24, 36, 48, 72, 96
Special precautions for disposal
MARKETING AUTHORISATION HOLDER
Bayer plc, Consumer Care Division
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.